We, for the first time, showed that RocA promoted STING-dependent infiltration and antitumor immunity of NK cells by targeting mtDNA, suggesting that RocA had a promising potential in cancer immunotherapy as a potent agonist of cGAS-STING. Here, STING1 is linked to cancer.